Business Context and Reporting Period
Mineralys Therapeutics, Inc. (MLYS) filed this Form 8-K on May 22, 2026, reporting events from its 2026 Annual Meeting of Stockholders held on May 21, 2026. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The filing reports the successful completion of the 2026 Annual Meeting. No material changes to financial position or operations are disclosed in this specific report.
Outlook, Management Commentary, and Voting Results
Both proposals submitted to stockholders were approved:
- Proposal 1 (Election of Directors): Three Class III directors were elected for a three-year term expiring in 2029.
- Srinivas Akkaraju, M.D., Ph.D.: 40,667,555 For; 26,447,538 Withhold.
- Brian Taylor Slingsby, M.D., Ph.D., M.P.H.: 42,487,140 For; 24,627,953 Withhold.
- Daphne Karydas: 66,626,766 For; 488,327 Withhold.
- Proposal 2 (Ratification of Auditors): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 72,648,272 For; 9,516 Against; 27,265 Abstain.
Management commentary and risk factors are referenced as being detailed in the definitive proxy statement filed on April 8, 2026.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 8, 2026, for detailed biographies of the newly elected directors and full risk disclosures.
- Confirm the total number of shares outstanding and voting rights structure to contextualize the "Withhold" votes for Dr. Akkaraju and Dr. Slingsby.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.